Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Journey Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Journey Medical's regulatory disclosures and financial reporting.
Pearce Michael Cooper reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Michael Cooper received a grant of 10,000 restricted stock units (RSUs). The award, granted on June 25, 2026 under the company’s 2015 Stock Plan, will vest in full as 10,000 shares on June 25, 2027. After this grant, Cooper directly holds 67,173 shares of Journey Medical common stock, including RSUs that vest over various time periods.
ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Lindsay A. Rosenwald, M.D. reported an equity compensation award rather than an open-market trade. On June 25, 2026, he was granted 10,000 restricted stock units that are scheduled to vest as 10,000 shares on June 25, 2027.
After this award, his direct holdings of common stock, including restricted stock units that vest over various periods, total 221,146 shares. A separate entry shows 176,470 shares held indirectly through a limited liability company over which he, as managing member, is deemed to have voting and investment power.
Journey Medical Corporation reported the results of its 2026 annual stockholder meeting held via virtual platform. Stockholders representing 16,145,526 shares of common stock and 6,000,000 shares of Class A common stock, together 81% of the 27,346,466 shares entitled to vote, were present, establishing a quorum.
All six director nominees were elected, each receiving over 31.7 million votes in favor, with broker non-votes of 6,515,971 for each nominee. Stockholders also ratified KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 39,374,407 votes for, 50,168 against, and 202,042 abstentions.
Journey Medical Corporation reported Q1 2026 revenue of $15.9 million, up 21% from Q1 2025, driven mainly by Emrosi sales of $6.3 million after its recent launch. Qbrexza and Accutane declined modestly, and foam franchise and legacy products fell more sharply due to competition.
The company narrowed its net loss to $2.2 million, or $(0.08) per share, compared with a $4.1 million loss a year earlier, helped by higher sales and stable operating costs. Cash and cash equivalents rose to $27.2 million, aided by positive operating cash flow of $2.9 million in the quarter.
Journey carries a $25.0 million term loan that bears interest at three‑month SOFR plus 7.75%, with principal payments scheduled to begin in February 2027. Despite improved results, management states that recurring and historical losses create substantial doubt about the company’s ability to continue as a going concern over the next twelve months.
Journey Medical Corporation reported strong top-line growth for the first quarter ended March 31, 2026. Total revenue rose 21% year-over-year to $15.96 million, driven largely by Emrosi®, which contributed $6.3 million in revenue as its prescription demand and payer coverage expanded.
The company still posted a GAAP net loss of $2.23 million, but this improved from a $4.07 million loss a year earlier. Loss per basic and diluted share narrowed to $(0.08) from $(0.18). Operating loss declined to $1.49 million from $3.32 million, reflecting better operating leverage from higher sales and disciplined spending.
On a non-GAAP basis, Adjusted EBITDA turned positive at $0.62 million, compared with a $(0.94) million Adjusted EBITDA loss in the prior-year quarter. Cash and cash equivalents increased to $27.22 million from $24.09 million at December 31, 2025, supporting management’s view that the company is well-positioned to continue executing its dermatology-focused growth strategy.
Journey Medical Corporation has issued its 2026 proxy statement for a virtual Annual Meeting on June 24, 2026 at 11:00 a.m. Eastern Time. Stockholders will vote on electing six directors for one-year terms and ratifying KPMG LLP as independent auditor for the year ending December 31, 2026.
The record date is April 28, 2026, with 21,346,446 shares of common stock and 6,000,000 shares of Class A common stock entitled to vote; each Class A share carries 3.91 votes. Directors, executive officers and 5% holders collectively beneficially own about 50.60% of outstanding common stock. The filing also details executive employment agreements, 2025 compensation and equity awards, director pay, audit fees, and governance policies including an insider trading policy and clawback policy.
Journey Medical Corp reports institutional ownership disclosure by Vanguard Capital Management. Vanguard Capital Management reports beneficial ownership of 1,206,395 shares of Common Stock, representing 5.65% of the class. The filing states Vanguard has sole dispositive power over 1,206,395 shares and sole voting power for 124,315 shares. The filing notes this reflects holdings across Vanguard affiliates and funds, per SEC Release No. 34-39538.
Journey Medical Corp Chief Operating Officer Ramsey Alloush received new equity awards as part of compensation. On April 22, 2026, he was granted 46,863 restricted stock units that vest in three equal installments on April 22 of 2027, 2028, and 2029. He also received stock options for 62,795 shares of common stock at an exercise price of $5.04 per share, vesting on the same dates. After these awards, he directly owns 598,543 shares of common stock, including restricted stock units. The options expire on April 22, 2036, giving him long-term upside exposure tied to the company’s share price.
Journey Medical Corp CFO Joseph Benesch received new equity awards as part of his compensation. On April 22, 2026, he was granted 28,907 restricted stock units that vest in three annual installments from April 2027 through April 2029. He also received 41,860 stock options with an exercise price of $5.04 per share, vesting annually over the same three-year period and expiring in 2036. After these awards, he directly holds 261,371 shares of common stock, and has 41,860 options outstanding.
Journey Medical Corp reported that President & CEO Claude Maraoui received new equity awards as part of his compensation. On April 22, 2026, he was granted 49,277 restricted stock units that vest in three equal annual installments from 2027 through 2029.
He was also granted stock options for 82,915 shares at an exercise price of $5.04 per share, vesting on the same 2027–2029 schedule and expiring in 2036. Following these grants, Maraoui directly holds 2,435,990 shares of common stock and 82,915 options.